Athenahealth Goes in Search of a Suitor

The transcript discusses a report from the New York Post about a bidding process for Athena, which is largely inaccurate. There are at least five bidders, both strategic and financial, with bids expected above $135 per share. Speculation surrounds Pamplona Capital and NThrive's involvement, though Athena has not engaged with them. Elliot, a significant shareholder, is expected to be part of the buyer group. The valuation is expected to be between $140 and $150 per share, with hopes of concluding the deal by the end of the month.

What is the expected bid price per share for Athenahealth according to the report?

• $160

• $140

• $135

• $120

What role does Elliot play in the Athenahealth sale process?

• They are not involved at all.

• They have been instrumental in the sale process.

• They are leading a competing bid.

• They are a minor shareholder.

What is the relationship between NThrive and Athenahealth as mentioned in the transcript?

• There is speculation about a merger.

• NThrive owns Athenahealth.

• They are confirmed to merge.

• NThrive is a competitor.

What is the expected high-end price range for Athenahealth's sale?

• $160 to $170

• $140 to $150

• $150 to $160

• $120 to $130

Who is the chairman of Athenahealth?

• Jonathan Bush

• Jeff Immelt

• Pamplona Capital

• Elliot